Ann: Notification regarding unquoted securities - NEU, page-9

Options are subject to the following vesting conditions:

(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase
2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;

(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a Marketing
Authorisation Application for trofinetide in the European Union, the United Kingdom or Japan.

(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.

If we can pass those hurdles, $8+ for sure.